Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

Escudier, Bernard; Eisen, Tim; M. Stadler, Walter; Szczylik, Cezary; Oudard, Stéphane; Staehler, Michael; Négrier, Sylvie; Chevreau, Christine; A. Desai, Apurva; Rolland, Frédéric; Demkow, Tomasz; E. Hutson, Thomas; Gore, Martin; Anderson, Sibyl; Hofilena, Gloria; Shan, Minghua; Peña, Carol; Lathia, Chetan; M. Bukowski, Ronald

doi:10.1200/jco.2008.19.5511

Public

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

Published in Journal of Clinical Oncology • May 18, 2009

Authors:

Bernard Escudier

Tim Eisen

Walter M. Stadler

Abstract

PURPOSE: Mature survival data and evaluation of vascular endothelial growth factor (VEGF) as a prognostic biomarker from the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) study in patients with renal cell carcinoma (RCC) are reported. PATIENTS AND METHODS: Nine hundred three ...

Subject

Sorafenib

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!